Reference

Medicinal composition of pioglitazone hydrochloride and glimepiride

All Rights Reserved. Medicinal composition of pioglitazone hydrochloride and glimepiride.In this study， 112529-15-4 and 93479-97-1 are also used. Chen, Ruijing (Beijing Rundekang Pharmaceutical Technology Co., Ltd., Peop. Rep. China). Faming Zhuanli Shenqing Gongkai Shuomingshu CN 1857264 A 8 Nov 2006, 9pp. (Chinese). (People's Republic of China). CODEN: CNXXEV. APPLICATION: CN 2010-75609 14 Apr 2006. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 2 The medicinal compn. of pioglitazone hydrochloride and glimepiride with a wt. ratio about 60-7.5:1 is formulated in to tablets, capsules, dispersible tablets, chewable tablets, orally disintegrating tablets and dripping pills, etc., for treating diabetes mellitus II. For example, pioglitazone hydrochloride 15 g, glimepiride 1 g and microcryst. cellulose 82 g are pulverized to 80 mesh, mixed, added with 90% ethanol followed by granule prepn. with 24 mesh, added magnesium stearate and tablets were made (1000 tablets). .

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes

All Rights Reserved. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes. A randomized trial. Mazzone, Theodore; Meyer, Peter M.; Feinstein, Steven B.; Davidson, Michael H.; Kondos, George T.; D'Agostino, Ralph B., Sr.; Perez, Alfonso; Provost, Jean-Claude; Haffner, Steven M. (Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Illinois College of Medicine, Chicago, USA). JAMA, the Journal of the American Medical Association, 296(21), 2572-2581 (English) 2006 American Medical Association.Chemicals with cas numbers 112529-15-4 and 93479-97-1 also play role. CODEN: JAMAAP. ISSN: 0098-7484. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Carotid artery intima-media thickness (CIMT) is a marker of coronary atherosclerosis and independently predicts cardiovascular events, which are increased in type 2 diabetes mellitus (DM). While studies of relatively short duration have suggested that thiazolidinediones such as pioglitazone might reduce progression of CIMT in persons with diabetes, the results of longer studies have been less clear. The aim was to evaluate the effect of pioglitazone vs glimepiride on changes in CIMT of the common carotid artery in patients with type 2 DM. Randomized, double-blind, comparator-controlled, multicenter trial in patients with type 2 DM conducted at 28 clin. sites in the multiracial/ethnic Chicago metropolitan area between Oct. 2003 and May 2006. The treatment period was 72 wk (1-wk follow-up). CIMT images were captured by a single ultrasonographer at 1 center and read by a single treatment-blinded reader using automated edge-detection technol. Participants were 462 adults (mean age, 60 [SD, 8.1] years; mean body mass index, 32 [SD, 5.1]) with type 2 DM (mean duration, 7.7 [SD, 7.2] years; mean glycosylated Hb [HbA1c] value, 7.4% [SD, 1.0%]), either newly diagnosed or currently treated with diet and exercise, sulfonyl-urea, metformin, insulin, or a combination thereof. Pioglitazone hydrochloride (15-45 mg/d) or glimepiride (1-4 mg/d) as an active comparator. Abs. change from baseline to final visit in mean posterior-wall CIMT of the left and right common carotid arteries. Mean change in CIMT was less with pioglitazone vs glimepiride at all time points (weeks 24, 48, 72). At week 72, the primary end point of progression of mean CIMT was less with pioglitazone vs glimepiride (-0.001 mm vs +0.012 mm, resp.; difference, -0.013 mm; 95% confidence interval, -0.024 to -0.002; P = .02). Pioglitazone also slowed progression of max. CIMT compared with glimepiride (0.002 mm vs 0.026 mm, resp., at 72 wk; difference, -0.024 mm; 95% confidence interval, -0.042 to -0.006; P = .008). The beneficial effect of pioglitazone on mean CIMT was similar across prespecified subgroups based on age, sex, systolic blood pressure, duration of DM, body mass index, HbA1c value, and statin use. Over an 18-mo treatment period in patients with type 2 DM, pioglitazone slowed progression of CIMT compared with glimepiride. .